Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLDI Calidi Biotherapeutics	$0.34 -0.1%	$0.43	$0.31 ▼ $3.89	$10.92M	1.07	893,560 shs	274,236 shs
ELYM Eliem Therapeutics	$1.26 -8.0%	$1.25	$2.35 ▼ $11.55	$37.49M	-0.39	486,688 shs	204,220 shs
ITRM Iterum Therapeutics	$1.00 -4.2%	$1.04	$0.81 ▼ $3.02	$39.84M	2.78	1.05 million shs	605,071 shs
QNTM Quantum Biopharma	$19.00 +23.6%	$9.52	$2.70 ▼ $19.09	$51.41M	0.54	955,610 shs	519,259 shs

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLDI Calidi Biotherapeutics	+6.83%	-5.70%	-22.51%	-55.80%	+34,389,900.00%
ELYM Eliem Therapeutics	+2.24%	+6.20%	+15.13%	+9.60%	-83.47%
ITRM Iterum Therapeutics	0.00%	+8.36%	+2.97%	-22.39%	-11.86%
QNTM Quantum Biopharma	+5.64%	+5.78%	+68.53%	+240.80%	+1,536,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLDI Calidi Biotherapeutics	1.5111 of 5 stars	3.5	3.0	0.0	0.0	0.0	0.0	0.6
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	2.3529 of 5 stars	3.5	5.0	0.0	0.0	2.5	0.0	0.0
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLDI Calidi Biotherapeutics	3.00	Buy	$10.00	2,812.06% Upside
ELYM Eliem Therapeutics	0.00	N/A	N/A	N/A
ITRM Iterum Therapeutics	3.00	Buy	$9.00	803.52% Upside
QNTM Quantum Biopharma	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest CLDI, ELYM, QNTM, and ITRM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
5/8/2025	ITRM Iterum Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$9.00

(Data available from 6/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLDI Calidi Biotherapeutics	$50K	218.35	N/A	N/A	($2.32) per share	-0.15
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	$3.90 per share	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	($0.12) per share	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	$21.29 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLDI Calidi Biotherapeutics	-$29.22M	N/A	0.00	N/A	N/A	N/A	N/A	-344.45%	N/A
ELYM Eliem Therapeutics	-$35.12M	-$0.53	N/A	∞	N/A	N/A	-47.03%	-45.97%	N/A
ITRM Iterum Therapeutics	-$24.77M	-$0.99	N/A	∞	N/A	N/A	N/A	-90.85%	8/13/2025 (Estimated)
QNTM Quantum Biopharma	-$17.90M	-$15.98	N/A	N/A	N/A	N/A	-84.21%	-62.63%	8/13/2025 (Estimated)

Latest CLDI, ELYM, QNTM, and ITRM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	QNTM Quantum Biopharma	-$0.37	-$1.41	-$1.04	-$3.53	$2.09 million	$2.09 million
5/13/2025	Q1 2025	ITRM Iterum Therapeutics	-$0.14	-$0.14	N/A	-$0.14	N/A	N/A
3/28/2025	Q4 2024	QNTM Quantum Biopharma	-$0.80	-$2.89	-$2.09	-$2.89	$0.92 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLDI Calidi Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ELYM Eliem Therapeutics	N/A	N/A	N/A	N/A	N/A
ITRM Iterum Therapeutics	N/A	N/A	N/A	N/A	N/A
QNTM Quantum Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLDI Calidi Biotherapeutics	N/A	0.19	0.19
ELYM Eliem Therapeutics	N/A	60.41	60.41
ITRM Iterum Therapeutics	N/A	1.41	1.41
QNTM Quantum Biopharma	N/A	3.76	3.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLDI Calidi Biotherapeutics	12.53%
ELYM Eliem Therapeutics	69.76%
ITRM Iterum Therapeutics	9.21%
QNTM Quantum Biopharma	1.24%

Insider Ownership

Company	Insider Ownership
CLDI Calidi Biotherapeutics	6.70%
ELYM Eliem Therapeutics	4.70%
ITRM Iterum Therapeutics	9.20%
QNTM Quantum Biopharma	8.53%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLDI Calidi Biotherapeutics	38	31.79 million	20.04 million	N/A
ELYM Eliem Therapeutics	9	29.75 million	28.35 million	Not Optionable
ITRM Iterum Therapeutics	10	40.00 million	31.40 million	Not Optionable
QNTM Quantum Biopharma	N/A	2.71 million	1.76 million	N/A

CLDI, ELYM, QNTM, and ITRM Headlines

Recent News About These Companies

Quantum BioPharma Boosts Digital Asset Holdings to $5 Million with New Bitcoin Purchase

June 10 at 4:33 PM | bitcoinmagazine.com

Quantum Biopharma (NASDAQ:QNTM) Stock Rating Upgraded by Wall Street Zen

June 8, 2025 | americanbankingnews.com

Quantum BioPharma clarifies misinformation on stock name, RTO rumors

June 4, 2025 | investing.com

Quantum BioPharma Clarifies Name Confusion, Refutes RTO Rumors With Unbuzzd Wellness

June 4, 2025 | nasdaq.com

Quantum BioPharma Clarifies It Has Not Changed Its Name

June 3, 2025 | globenewswire.com

iNGENū CRO Partners with Quantum BioPharma to Launch Pioneering Australian Clinical Trial for Chronic Nociplastic Pain in MCAS Patients

June 2, 2025 | globenewswire.com

Quantum BioPharma settles disputes with former CEO

June 1, 2025 | uk.investing.com

What's Going On With Quantum Biopharma Stock Today?

May 30, 2025 | benzinga.com

Quantum BioPharma Receives $2.35 Million USD from a Mutually-Agreed Global Legal Settlement with Dr. Raza Bokhari

May 30, 2025 | globenewswire.com

Quantum Biopharma Licensee Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name To Unbuzzd Wellness Inc.

May 29, 2025 | globenewswire.com

Quantum BioPharma Receives Ethics Committee Approval for Phase 2 Clinical Trial of FSD202 for Nociplastic Pain in Patients with Idiopathic Mast Cell Activation Syndrome

May 28, 2025 | globenewswire.com

Quantum BioPharma Increases Crypto Holdings To $4.5 Mln For Strategic Growth

May 21, 2025 | nasdaq.com

Quantum BioPharma Partners with BitGo to Securely Store its Crypto Currency Assets

May 21, 2025 | thestar.com

Quantum Biopharma Announces Signing of an Agreement with a Global Pharmaceutical Contract Research Organization to Prepare an IND (Investigational New Drug) Application Package for Lucid-21-302 (Lucid-MS), A First-In-Class Treatment for Multiple Sclerosis

May 20, 2025 | globenewswire.com

Quantum Biopharma Purchases an Additional USD $1 Million of Bitcoin and Other Cryptocurrencies to Hold BTC Treasury and To Generate Staking Revenue. Bringing the Total Investment in Digital Assets to USD $4,500,000

May 19, 2025 | globenewswire.com

Quantum BioPharma to Attend Sidoti Micro-Cap Investor Conference and the AGP Virtual Healthcare Conference

May 16, 2025 | globenewswire.com

Quantum BioPharma Completes Dosing in 90-Day Toxicity Studies for Multiple Sclerosis Drug Lucid-21-302, Advancing Toward IND Submission

May 13, 2025 | nasdaq.com

Quantum Biopharma to seek FDA OK for Phase 2 trial of Lucid-MS

May 13, 2025 | multiplesclerosisnewstoday.com

Quantum BioPharma Announces Completion of Dosing in 90-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-MS for Multiple Sclerosis

May 12, 2025 | globenewswire.com

Quantum BioPharma Ltd. (QNTM) Business Update Conference Call Transcript

May 6, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDI, ELYM, QNTM, and ITRM Company Descriptions

Calidi Biotherapeutics NYSE:CLDI

$0.34 0.00 (-0.15%)

As of 04:00 PM Eastern

Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing allogeneic stem cell-based platforms to potentiate and deliver oncolytic viruses to cancer patients in the United States. Its product pipeline comprising CLD-101, which is in phase 1b clinical trial for the treatment of high grade glioma; CLD-101, which is in phase 1 clinical trial for the treatment of recurrent high grade glioma; CLD-201, which is in preclinical trial for the treatment of advanced solid tumors, such as triple-negative breast cancer, metastatic/unresectable melanoma, head and neck squamous cell carcinoma, advanced soft tissue sarcoma, and advanced basal cell carcinoma; and CLD-400, which is in preclinical trial for the treatment of lung cancer and metastatic solid tumors. The company offers NeuroNova platform and SuperNova platform. The company is headquartered in San Diego, California.

Eliem Therapeutics NASDAQ:ELYM

$1.26 -0.11 (-8.03%)

As of 06/11/2025

Eliem Therapeutics, Inc., a biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in psychiatry, epilepsy, chronic pain, and other disorders of the peripheral and central nervous systems. The company was incorporated in 2018 and is headquartered in Wilmington, Delaware.

Iterum Therapeutics NASDAQ:ITRM

$1.00 -0.04 (-4.22%)

As of 04:00 PM Eastern

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Quantum Biopharma NASDAQ:QNTM

$19.00 +3.63 (+23.62%)

As of 04:00 PM Eastern

Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time